1 / 7

MDS Classification and Prognosis

MDS Classification and Prognosis. John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation. Primary Myelodysplastic Syndromes. Malignant disorders characterized by Ineffective hematopoiesis (≥ 1 lineage) Variable % of leukemic blasts

faye
Télécharger la présentation

MDS Classification and Prognosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical CenterHematomorphologistChair, MDS Foundation

  2. Primary Myelodysplastic Syndromes • Malignant disorders characterized by • Ineffective hematopoiesis (≥ 1 lineage) • Variable % of leukemic blasts • Median age is 70 • 30% progress to AML • US incidence: ~15,000 cases annually • US prevalence: 35,000 to 55,000 • Majority present with moderate to severe anemia • Del 5q is associated with transfusion-dependent refractory anemia

  3. International Prognostic Scoring System All 3 prognostic variables required to generate IPSS score Greenberg P, et al. Blood. 1997;89:2079-2088.

  4. IPSS Risk Category Correlates With MDS Survival Outcomes 100 80 del(5)(q13q33) 60 Percent surviving 40 Low 20 Int-1 Int-2 High 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Time, yr Greenberg P, et al. Blood. 1997;89:2079-2088.

  5. Treatment: Recombinant erythroid growth factors 5-azacytidine (Vidaza®) Transfusions Management of Low/Int-1-Risk MDS Patients with MDS present with anemia and fatigue

  6. Transfusions: An Imperfect Solution • Transient Hct improvement • Hct not restored to normal • Associated morbidities • Iron overload (250 mg iron/unit) • Unable to be phlebotimized • Requires chelation • Infectious diseases • Transfusion reactions • Demand on blood supply • Impact on patients’ lives

  7. Impact of Lenalidomide on a Patient • Patient #014-3002 • 84-yr-old female with Low-Risk MDS; del 5q • Required 116 RBC units over 54 mo • EPO resistant • Chelation therapy for iron overload • Started lenalidomide: Dec 03 (Hgb: 8.2 g %) • Last unit transfused: Feb 04; Hgb: 10.0 g % by Day 50 • Hgb 13.3 g % by Apr 04 • Has remained at that level to present • Tolerating phlebotomy for iron overload • Marrow morphology and cytogenetics normalized • Remains on study in complete remission

More Related